Biosimilars Oncology Roundup for June 2024—Podcast Edition

On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.

Show notes

1. Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships

2. Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology

3. EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions

4. New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers

5. ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars

6. ASCO 2024 Posters Showcase Positive Data on Denosumab, Pegfilgrastim Biosimilars

7. Authors Spotlight Long-Term Solutions to Ensure Biosimilar Market Sustainability

8. Part 2: Unlocking the Potential of Biosimilars to Improve Health Equity